Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer

Giulia Pellizzari; Heather J. Bax; Debra H. Josephs; Jelena Gotovina; Erika Jensen-Jarolim; James F. Spicer; Sophia N. Karagiannis

doi:10.1016/j.molmed.2020.03.002

Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer

Giulia Pellizzari, Heather J. Bax, Debra H. Josephs, Jelena Gotovina, Erika Jensen-Jarolim, James F. Spicer^*, Sophia N. Karagiannis

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

55 Downloads (Pure)

Abstract

Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing of the unique biological properties of a different class, IgE, could engender potent effector cell activation and unleash previously-untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE feature very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). Here we review pre-clinical studies that point towards control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. Further, we discuss the clinical development harnessing the anti-tumor potential of recombinant IgE antibodies in cancer patients.

Original language	English
Pages (from-to)	615-626
Number of pages	12
Journal	TRENDS IN MOLECULAR MEDICINE
Volume	26
Issue number	6
DOIs	https://doi.org/10.1016/j.molmed.2020.03.002
Publication status	Published - Jun 2020

Keywords

AllergoOncology
cancer
cancer immunotherapy
FcεRI
IgE
macrophages
monocytes
tumor-associated macrophage

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.molmed.2020.03.002

Harnessing therapeutic IgE antibodies_PELLIZZARI_Accepted9March2020_GREEN AAMAccepted author manuscript, 4.77 MBLicence: CC BY-NC-ND

Cite this

@article{6eece225de554d01a37d59b144ee45b0,

title = "Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer",

abstract = "Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing of the unique biological properties of a different class, IgE, could engender potent effector cell activation and unleash previously-untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE feature very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). Here we review pre-clinical studies that point towards control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. Further, we discuss the clinical development harnessing the anti-tumor potential of recombinant IgE antibodies in cancer patients. ",

keywords = "AllergoOncology, cancer, cancer immunotherapy, FcεRI, IgE, macrophages, monocytes, tumor-associated macrophage",

author = "Giulia Pellizzari and Bax, {Heather J.} and Josephs, {Debra H.} and Jelena Gotovina and Erika Jensen-Jarolim and Spicer, {James F.} and Karagiannis, {Sophia N.}",

year = "2020",

month = jun,

doi = "10.1016/j.molmed.2020.03.002",

language = "English",

volume = "26",

pages = "615--626",

journal = "TRENDS IN MOLECULAR MEDICINE",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer

AU - Pellizzari, Giulia

AU - Bax, Heather J.

AU - Josephs, Debra H.

AU - Gotovina, Jelena

AU - Jensen-Jarolim, Erika

AU - Spicer, James F.

AU - Karagiannis, Sophia N.

PY - 2020/6

Y1 - 2020/6

N2 - Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing of the unique biological properties of a different class, IgE, could engender potent effector cell activation and unleash previously-untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE feature very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). Here we review pre-clinical studies that point towards control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. Further, we discuss the clinical development harnessing the anti-tumor potential of recombinant IgE antibodies in cancer patients.

AB - Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing of the unique biological properties of a different class, IgE, could engender potent effector cell activation and unleash previously-untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE feature very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). Here we review pre-clinical studies that point towards control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. Further, we discuss the clinical development harnessing the anti-tumor potential of recombinant IgE antibodies in cancer patients.

KW - AllergoOncology

KW - cancer

KW - cancer immunotherapy

KW - FcεRI

KW - IgE

KW - macrophages

KW - monocytes

KW - tumor-associated macrophage

UR - http://www.scopus.com/inward/record.url?scp=85082798583&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2020.03.002

DO - 10.1016/j.molmed.2020.03.002

M3 - Review article

C2 - 32470387

AN - SCOPUS:85082798583

SN - 1471-4914

VL - 26

SP - 615

EP - 626

JO - TRENDS IN MOLECULAR MEDICINE

JF - TRENDS IN MOLECULAR MEDICINE

IS - 6

ER -

Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this